To include your compound in the COVID-19 Resource Center, submit it here.

Firazyr icatibant regulatory update

FDA's Pulmonary-Allergy Drugs Advisory Committee will meet on June 23 to discuss an NDA from

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE